Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 3;9(1):00442-2022.
doi: 10.1183/23120541.00442-2022. eCollection 2023 Jan.

Adverse perception of cough in patients with severe asthma: a discrete choice experiment

Joshua Holmes  1 , Vikki O'Neill  2 , Lorcan P McGarvey  1 , Liam G Heaney  1
Affiliations

Adverse perception of cough in patients with severe asthma: a discrete choice experiment

Joshua Holmes et al. ERJ Open Res. .

Abstract

Background: Asthma symptoms adversely impact quality of life in particular in those with poor disease control. Commonly used patient-reported measures for asthma used to assess asthma control often inadequately capture the impact of cough, despite evidence that cough is one of the most bothersome symptoms for patients with asthma. This study aims to improve our understanding of how patients with asthma perceive cough to better understand its clinical impact.

Methods: A discrete choice experiment (DCE) was performed in two distinct adult asthma populations; those with severe asthma as defined by Global Initiative for Asthma (GINA) step 4/5 classification and those with moderate asthma (a GINA steps 2 or 3 classification of asthma severity).

Results: Choices were highly dominated by the cough attribute in the symptoms complexes; 48.4% of patients with severe asthma and 31.3% with moderate asthma consistently chose the alternative with the lowest level of cough. Furthermore, cough predominance was found to be significantly associated with severity of asthma (p=0.047). Patients with moderate asthma were not willing to accept any additional symptoms to reduce cough from severe to mild. However, these patients were willing to accept mild breathlessness, mild sleep disturbance, severe chest tightness and severe wheezing to remove coughing altogether.

Conclusions: Patients with asthma prefer to have less cough and are willing to accept greater levels of other symptoms to achieve this. Additionally, asthma severity may influence an individual's perception of their symptoms; cough is a more important symptom for patients with severe asthma than those with a milder disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Holmes has no conflict of interest to declare Conflict of interest: V. O'Neill has no conflict of interest to declare Conflict of interest: L.P. McGarvey has received grants and personal fees from Afferent Pharmaceuticals and Merck Sharp & Dohme; personal fees from Applied Clinical Intelligence; grants from Asthma UK, Northern Ireland Chest Heart and Stroke, NC3Rs, British Heart Foundation, and Chiesi; travel and subsistence for attendance at scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, and Chiesi; and advisory board or consultancy fees from Almirall, NAPP, GlaxoSmithKline, and Boehringer Ingelheim. Conflict of interest: L.G. Heaney has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/Genentech Inc, and Glaxo Smith Kline, Amgen, Genentech/Hoffman la Roche, Astra Zeneca, MedImmune, Glaxo Smith Kline, Aerocrine and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen

Figures

FIGURE 1
FIGURE 1
Example layout of a discrete choice scenario.
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma . 2022 GINA Report: Global Strategy for Asthma Management and Prevention. 2022. Available from: http://ginasthma.org/
    1. Juniper EF, Wisniewski ME, Cox FM, et al. . Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004; 23: 287–291. doi:10.1183/09031936.04.00064204 - DOI - PubMed
    1. Serra-Batlles J, Plaza V, Morejón E, et al. . Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322–1326. doi:10.1183/09031936.98.12061322 - DOI - PubMed
    1. Juniper EF, O'Byrne PM, Guyatt GH, et al. . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902–907. doi:10.1034/j.1399-3003.1999.14d29.x - DOI - PubMed
    1. Juniper EF, Guyatt GH, Epstein RS, et al. . Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83. - PMC - PubMed

LinkOut - more resources